title: Substrate deprivation therapy in juvenile Sandhoff disease.
abstract: Substrate deprivation therapy has been successfully applied in a number of lysosomal storage diseases, such as Gaucher disease. So far only limited experience is available in Sandhoff disease. We initiated substrate deprivation therapy in one male patient, who initially presented at the age of 3.5 years with epilepsy and regression in motor skills and speech development. Juvenile Sandhoff disease was diagnosed on the basis of a decreased hexosaminidase activity in leukocytes and a homozygous HEXB gene mutation. After the epilepsy was controlled, the clinical course remained stable for years, defined by a mild proximal myopathy and stable mental retardation. At 14 years of age the patient experienced a second episode with progressively worsening general condition with diminishing muscle power and progressive ataxia. Treatment was started with the N-alkylated imino sugar miglustat, inhibiting the glucosylceramide synthase, an essential enzyme for the synthesis of glycosphingolipids. Diarrhoea was treated with lactose restriction. We performed detailed biochemical investigations, motor and mental development analysis, brain imaging, organ function studies and quality of life score prior to and at different time points after start of the treatment. Two years after the initiation of therapy the patient has a stable neurological picture without further regression in his motor development, ataxia or intelligence. There is a subjective improvement in the fine motor skills and walking up the stairs but no change in the quality of life score. Under treatment with miglustat the clinical course in our patient with Sandhoff disease did not further deteriorate.
authors.affiliation: Department of Paediatrics, Radboud University Nijmegen Medical Centre, huispost 833, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. s.wortmann@cukz.umcn.nl
authors.forename: S B
authors.initials: SB
authors.lastname: Wortmann
authors.forename: D J
authors.initials: DJ
authors.lastname: Lefeber
authors.forename: G
authors.initials: G
authors.lastname: Dekomien
authors.forename: M A A P
authors.initials: MA
authors.lastname: Willemsen
authors.forename: R A
authors.initials: RA
authors.lastname: Wevers
authors.forename: E
authors.initials: E
authors.lastname: Morava
mesh_terms: D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000293:Adolescent; D002675:Child, Preschool; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors; D054819:Hexosaminidase B / Q000235:genetics; D006801:Humans; D008297:Male; D009154:Mutation; D012497:Sandhoff Disease / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology
chemical_list: D004791:Enzyme Inhibitors; D017485:1-Deoxynojirimycin; C059896:miglustat; D005964:Glucosyltransferases; C023246:ceramide glucosyltransferase; D054819:Hexosaminidase B